EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Sodium–glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study

Anne Chang iD, Tien-Chun Yang, Anna Chang, Chien-Tai Hong, Ying-Hsuan Tai

Sage Open Chronic Disease · 2026-02 · 17

DOI: 10.1177/27558428261449950 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Sage Open Chronic Disease, online erschienen am 24.05.2026. Verfasst von Anne Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits in type 2 diabetes mellitus (T2DM).

Objectives

This study investigated the association between SGLT2 inhibitor therapy and mortality and morbidity after hospitalization for pneumonia among adults with T2DM.

Design

International retrospective propensity score-matched cohort study.

Methods

We conducted a cohort study using the TriNetX database, including adults with T2DM who were hospitalized for pneumonia between January 1, 2013, and March 31, 2025. Patients were categorized based on whether they had received a prescription for SGLT2 inhibitors within 90 days before the index admission. The primary outcome was all-cause mortality within 30 days. Secondary outcomes included major adverse respiratory events (MAREs, comprising respiratory failure, acute respiratory distress syndrome, pleural effusion or empyema, sepsis, mechanical ventilation, and intensive care unit admission), acute kidney injury (AKI), and diabetic ketoacidosis (DKA).

Results

Among the 6505 matched patients, SGLT2 inhibitor users had significantly lower 30-day mortality (8.72% vs 12.27%; relative risk (RR): 0.71, 95% confidence interval (CI): 0.64–0.79, p < 0.0001), MAREs (RR: 0.87, 95% CI: 0.84–0.91, p < 0.0001), AKI (RR: 0.89, 95% CI: 0.84–0.94, p < 0.0001). Diabetic ketoacidosis (DKA) events were rare in both groups (0.25% vs 0.46%) but occurred less frequently among SGLT2 inhibitor users (RR: 0.53, 95% CI: 0.29–0.98, p = 0.0387). These findings were consistent across multiple follow-up periods and sensitivity analyses. Additionally, a dose–response relationship was observed between the duration of SGLT2 inhibitor use and reduced rates of all-cause mortality, MAREs, and AKI.

Conclusion

Patients with T2DM who used SGLT2 inhibitors had significantly lower risks of mortality and morbidity following hospitalization for pneumonia, including a notable reduction in DKA, contrary to prior concerns. Randomized controlled trials are warranted to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

acute kidney injuryall-cause mortalitydiabetic ketoacidosismajor adverse respiratory eventpneumonia

Autor:innen und Institutionen

  • Department of Endocrinology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
  • Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taiwan.
  • Department of Neurology, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan.
  • Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
  • Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taiwan.
  • Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.

ORCID-Profile: Anne Chang

Förderung

  • Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare

Zitieren

APA

Chang, A., Yang, T. C., Chang, A., Hong, C. T., & Tai, Y. H. (2026). Sodium–glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study. Sage Open Chronic Disease, 17. https://doi.org/10.1177/27558428261449950

Vancouver

Chang A, Yang TC, Chang A, Hong CT, Tai YH. Sodium–glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study. Sage Open Chronic Disease. 2026;17. doi:10.1177/27558428261449950

BibTeX
@article{Chang2026,
  author = {Chang, Anne and Yang, Tien-Chun and Chang, Anna and Hong, Chien-Tai and Tai, Ying-Hsuan},
  title = {Sodium–glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study},
  journal = {Sage Open Chronic Disease},
  year = {2026},
  volume = {17},
  doi = {10.1177/27558428261449950}
}
Kostenlos starten →